These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 32325836)

  • 1. Pro-Arrhythmic Signaling of Thyroid Hormones and Its Relevance in Subclinical Hyperthyroidism.
    Tribulova N; Kurahara LH; Hlivak P; Hirano K; Szeiffova Bacova B
    Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32325836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Both hypothyroidism and hyperthyroidism increase atrial fibrillation inducibility in rats.
    Zhang Y; Dedkov EI; Teplitsky D; Weltman NY; Pol CJ; Rajagopalan V; Lee B; Gerdes AM
    Circ Arrhythm Electrophysiol; 2013 Oct; 6(5):952-9. PubMed ID: 24036190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The bidirectional relationship of thyroid disease and atrial fibrillation: Established knowledge and future considerations.
    Bekiaridou A; Kartas A; Moysidis DV; Papazoglou AS; Baroutidou A; Papanastasiou A; Giannakoulas G
    Rev Endocr Metab Disord; 2022 Jun; 23(3):621-630. PubMed ID: 35112273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical review 142: cardiac dysrhythmias and thyroid dysfunction: the hidden menace?
    Osman F; Gammage MD; Sheppard MC; Franklyn JA
    J Clin Endocrinol Metab; 2002 Mar; 87(3):963-7. PubMed ID: 11889143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atrial fibrillation is associated with increased risk of lethal ventricular arrhythmias.
    Kim YG; Choi YY; Han KD; Min K; Choi HY; Shim J; Choi JI; Kim YH
    Sci Rep; 2021 Sep; 11(1):18111. PubMed ID: 34518592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sudden cardiac death complicating newly diagnosed atrial fibrillation in the setting of subclinical hyperthyroidism.
    Mountantonakis SE; Cruz Palma E
    J Electrocardiol; 2008; 41(6):659-61. PubMed ID: 18367197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Challenges in the Management of Atrial Fibrillation With Subclinical Hyperthyroidism.
    Gencer B; Cappola AR; Rodondi N; Collet TH
    Front Endocrinol (Lausanne); 2021; 12():795492. PubMed ID: 35058884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thyroid hormones and cardiac arrhythmias.
    Tribulova N; Knezl V; Shainberg A; Seki S; Soukup T
    Vascul Pharmacol; 2010; 52(3-4):102-12. PubMed ID: 19850152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular characterization of thyroid hormone-inhibited atrial L-type calcium channel expression: implication for atrial fibrillation in hyperthyroidism.
    Chen WJ; Yeh YH; Lin KH; Chang GJ; Kuo CT
    Basic Res Cardiol; 2011 Mar; 106(2):163-74. PubMed ID: 21234757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of thyroid dysfunction in patients with paroxysmal atrial fibrillation.
    Vergara P; Picardi G; Nigro G; Scafuro F; de Chiara A; Calabrò R; Vergara G
    Anadolu Kardiyol Derg; 2007 Jul; 7 Suppl 1():104-6. PubMed ID: 17584697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Arrhythmogenic implications of non-iatrogenic thyroid dysfunction].
    Inama G; Furlanello F; Fiorentini F; Braito G; Vergara G; Casana P
    G Ital Cardiol; 1989 Apr; 19(4):303-10. PubMed ID: 2753273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atrial Fibrillation and Ventricular Arrhythmias: Sex Differences in Electrophysiology, Epidemiology, Clinical Presentation, and Clinical Outcomes.
    Gillis AM
    Circulation; 2017 Feb; 135(6):593-608. PubMed ID: 28153995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thyroid hormones and the heart.
    Vargas-Uricoechea H; Sierra-Torres CH
    Horm Mol Biol Clin Investig; 2014 Apr; 18(1):15-26. PubMed ID: 25389997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of device detected atrial and ventricular tachyarrhythmia with adverse events in patients with an implantable cardioverter-defibrillator.
    Abbas H; Younis A; Goldenberg I; McNitt S; Aktas MK; Tabaja C; Ojo A
    J Cardiovasc Electrophysiol; 2024 Jun; 35(6):1203-1211. PubMed ID: 38606650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk assessment in the development of atrial fibrillation at patients with associate thyroid dysfunctions.
    Tănase DM; Ionescu SD; Ouatu A; Ambăruş V; Arsenescu-Georgescu C
    Rev Med Chir Soc Med Nat Iasi; 2013; 117(3):623-9. PubMed ID: 24502026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of thyroid hormones on the heart.
    Vargas-Uricoechea H; Bonelo-Perdomo A; Sierra-Torres CH
    Clin Investig Arterioscler; 2014; 26(6):296-309. PubMed ID: 25438971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. History of hyperthyroidism and long-term outcome of catheter ablation of drug-refractory atrial fibrillation.
    Wongcharoen W; Lin YJ; Chang SL; Lo LW; Hu YF; Chung FP; Chong E; Chao TF; Tuan TC; Chang YT; Lin CY; Liao JN; Lin YC; Chen YY; Chen SA
    Heart Rhythm; 2015 Sep; 12(9):1956-62. PubMed ID: 26049050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thyroid hormone and the cardiovascular system.
    Klein I; Ojamaa K
    N Engl J Med; 2001 Feb; 344(7):501-9. PubMed ID: 11172193
    [No Abstract]   [Full Text] [Related]  

  • 19. Antiarrhythmic drugs in patients with implantable cardioverter-defibrillators.
    Bollmann A; Husser D; Cannom DS
    Am J Cardiovasc Drugs; 2005; 5(6):371-8. PubMed ID: 16259525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Outcomes and Characteristics With Dofetilide in Atrial Fibrillation Patients Considered for Implantable Cardioverter-Defibrillator.
    Koene RJ; Menon V; Cantillon DJ; Dresing TJ; Martin DO; Kanj M; Saliba WI; Tarakji KG; Baranowski B; Hussein AA; Tchou PJ; Bhargava M; Callahan TD; Rickard JW; Niebauer MJ; Chung MK; Varma N; Wilkoff BL; Lindsay BD; Wazni OM
    Circ Arrhythm Electrophysiol; 2020 Jul; 13(7):e008168. PubMed ID: 32538135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.